SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive mucoadhesion data for its intranasal Naloxone program, sparking excitement about its potential as a multi-day runner. Community discussions revolve around the significance of the manufacturing milestone and superior data, while some traders are wary of potential dilution given the company's history and low float. The stock is also gaining attention within the context of other low-float Israeli stocks experiencing significant moves.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the quantum computing sector garners attention, with discussions focusing on its superconducting QPU systems and potential for scalability compared to other quantum computing approaches. Community members debate the company's valuation relative to its revenue and the competitive landscape, while also discussing potential catalysts and trading strategies involving options. Some are optimistic about Rigetti's technology and long-term potential, while others express skepticism, citing concerns about profitability and competition from larger companies.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders discuss its potential for institutional adoption and retail activity, specifically meme coins. Community members are analyzing entry points and debating its ability to outperform other cryptos, while some express concern over recent price drops. Bullish sentiment revolves around potential rallies and strong community support.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending due to its recent earnings report, which showed record revenue and profit, sparking discussions about its undervaluation relative to competitors like HOOD. The community is highlighting the company's strong growth in global client assets and its potential for significant price appreciation, drawing comparisons to HOOD's earlier run-up.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about a potential acquisition of Warner Bros. Discovery, with many debating whether the deal would be beneficial. Community discussions revolve around potential price targets and technical analysis, while some express concerns about the company's recent performance and programming decisions. The possibility of a bidding war with other major players like Comcast and Paramount Skydance is also fueling the conversation.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending amid speculation and excitement around the robotics sector, driven by potential government support and company-specific developments like overnight trading highs and high trading volumes. Community members are actively discussing potential short squeezes and comparing SERV to other robotics plays, anticipating further gains and focusing on the company's growth prospects with its DoorDash partnership. Some see a buying opportunity, while others are wary, pointing to past volatility and dilution.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending following the release of its Q3 earnings, which beat analyst expectations and showed profitability. The community is actively discussing the company's growth, partnerships, and potential for a continued uptrend, while also debating its valuation relative to peers and the impact of short positions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the revival of OG memes on the Solana blockchain. Community members emphasize consistent engagement and building a strong culture, expressing conviction that $RAGE represents more than just a coin. Discussions highlight the importance of community over charts, with members actively working towards broader recognition and adoption.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as investors react to the company's announcement of a new U.S. Government Business Unit and recent analyst coverage with an outperform rating. Community discussions revolve around potential government contracts and the company's prospects within the quantum computing sector.  Despite being unprofitable, some investors are drawn to QBTS as a pure-laser computing play and a potential beneficiary of growing AI energy demands.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending amid mixed sentiment following recent trial setbacks and shareholder lawsuits, though analysts see potential upside and key readouts are expected in the coming quarters. Community members are weighing the risks against the potential for a buyout, drawing comparisons to other biotech successes, and closely watching the upcoming FDA meeting for clarity. Discussions also focus on technical analyses, potential market size, and institutional investment activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of pharma giant Eli Lilly &amp; Co (LLY) jumped over 13% on Thursday after the company surpassed Wall Street’s second-quarter estimates and raised its full-year guidance.The firm reported earnings per share (EPS) of $3.92 compared to an estimate of $2.60 while revenue came in at $11.30 billion versus an estimate of $9.92 billion.However, the highlight of the earnings report came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. Management’s upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.Eli Lilly also increased its EPS guidance to the range of $15.10 to $15.60 on a reported basis compared to a previous guidance of $13.05 to $13.55. Non-GAAP EPS is expected to come in at $16.10-16.60 compared to prior guidance of $13.50-14.00.Following the upbeat announcement, retail sentiment on Eli Lilly continued to trend in the ‘bullish’ territory (65/100) amid ‘high’ message volumes.<figure class="image"><a href="https://stocktwits.com/symbol/LLY"><img style="aspect-ratio:1882/522;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_08_at_9_19_54_AM_bfa85cd852.png" alt="Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024" width="1882" height="522"></a><figcaption>Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024</figcaption></figure>David A. Ricks, Lilly's chair and CEO said Mounjaro, Zepbound and Verzenio led the firm’s strong financial performance during the quarter. "We also recently received approval of Kisunla to help people with Alzheimer's disease, a moment that was decades in the making,” he said.During the second quarter, worldwide Mounjaro revenue stood at $3.09 billion versus $979.70 million in Q2 2023. Mounjaro is an injectable medicine for type-2 diabetes in adults. Zepbound, which launched in the U.S. for the treatment of adult patients with obesity or overweight with weight-related co-morbidities, saw U.S. revenue come in at $1.24 billion.The firm’s pipeline progress included approval of Kisunla in the U.S. for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma.Some Stocktwits users, including "HighBetaAlgorithms" are bullish on the stock given that obesity has been a widespread problem in the U.S. and a growing concern globally.<stembedurl>https://stocktwits.com/HighBetaAlgorithms/message/582263226</stembedurl>

Eli Lilly reported earnings per share of $3.92 compared to an estimate of $2.60

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion, Draws Retail Cheer

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. 

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion

Equity

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. The upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.

CURE
Direxion Daily Healthcare Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CURE News

CUREDirexion Daily Healthcare Bull 3X Shares